BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 37422523)

  • 1. The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: A review.
    Vanden Berg RNW; Zilli T; Achard V; Dorff T; Abern M
    Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):702-711. PubMed ID: 37422523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is the ideal combination therapy in de novo, oligometastatic, castration-sensitive prostate cancer?
    Baboudjian M; Roubaud G; Fromont G; Gauthé M; Beauval JB; Barret E; Brureau L; Créhange G; Dariane C; Fiard G; Mathieu R; Ruffion A; Rouprêt M; Renard-Penna R; Sargos P; Ploussard G;
    World J Urol; 2023 Aug; 41(8):2033-2041. PubMed ID: 36484817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Radiotherapy for local disease in metastatic prostate cancer.].
    Cambeiro M; Calvo FA
    Arch Esp Urol; 2018 Mar; 71(3):298-305. PubMed ID: 29633951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cytoreductive radical prostatectomy in metastatic prostate cancer.
    Vladimír Š; Zuzana S; Hana Š
    Klin Onkol; 2022; 35(1):55-62. PubMed ID: 35236082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
    Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
    Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review.
    Farolfi A; Hadaschik B; Hamdy FC; Herrmann K; Hofman MS; Murphy DG; Ost P; Padhani AR; Fanti S
    Eur Urol Oncol; 2021 Oct; 4(5):714-730. PubMed ID: 33750684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer: A Phase II Randomized Controlled Trial.
    Dai B; Zhang S; Wan FN; Wang HK; Zhang JY; Wang QF; Kong YY; Ma XJ; Mo M; Zhu Y; Qin XJ; Lin GW; Ye DW
    Eur Urol Oncol; 2022 Oct; 5(5):519-525. PubMed ID: 35780048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastasis-Directed Therapy for Oligometastatic Castration-Sensitive Prostate Cancer: An Alternative to ADT?
    Cahill EM; Pfail JL; Fu MZ; Saraiya B; Mayer T; Stephenson RD; Ennis RD; Hathout L; Deek MP; Ghodoussipour S; Jang TL
    Curr Urol Rep; 2023 Jul; 24(7):299-306. PubMed ID: 37017928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current role of precision surgery in oligometastatic prostate cancer.
    von Deimling M; Rajwa P; Tilki D; Heidenreich A; Pallauf M; Bianchi A; Yanagisawa T; Kawada T; Karakiewicz PI; Gontero P; Pradere B; Ploussard G; Rink M; Shariat SF
    ESMO Open; 2022 Dec; 7(6):100597. PubMed ID: 36208497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastasis-directed therapy in oligometastatic prostate cancer.
    Miszczyk M; Soeterik T; Marra G; Matsukawa A; Shariat SF
    Curr Opin Urol; 2024 May; 34(3):178-182. PubMed ID: 38426229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer.
    Kothari G; Ost P; Cheung P; Blanchard P; Tree AC; van As NJ; Lo SS; Moghanaki D; Loblaw A; Siva S
    Curr Oncol Rep; 2019 Mar; 21(5):43. PubMed ID: 30919165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local Therapeutics for the Treatment of Oligo Metastatic Prostate Cancer.
    Jalfon MJ; Sakhalkar OV; Lokeshwar SD; Marks VA; Choksi AU; Klaassen Z; Leapman MS; Kim IY
    Curr Urol Rep; 2023 Oct; 24(10):455-461. PubMed ID: 37369828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focal therapy for primary tumor and metastases in de novo or recurrent oligometastatic prostate cancer: current standing and future perspectives.
    Tsaur I; Blaheta RA; Dotzauer R; Brandt MP; Gandaglia G; Sinescu I; Mirvald C; Olivier J; Surcel C;
    World J Urol; 2023 Aug; 41(8):2077-2090. PubMed ID: 36183289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time.
    Dhondt B; De Bleser E; Claeys T; Buelens S; Lumen N; Vandesompele J; Beckers A; Fonteyne V; Van der Eecken K; De Bruycker A; Paul J; Gramme P; Ost P
    World J Urol; 2019 Dec; 37(12):2557-2564. PubMed ID: 30578441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncological and perioperative outcomes of surgery with or without metastasis-directed therapy as part of a multimodal treatment in men with de-novo oligometastatic prostate cancer.
    Pellegrino A; Gandaglia G; de Angelis M; Fallara G; Mazzone E; Stabile A; Pellegrino F; Robesti D; Leni R; Scuderi S; Cucchiara V; Cirulli GO; Barletta F; Montorsi F; Briganti A
    World J Urol; 2023 Aug; 41(8):2069-2076. PubMed ID: 37326656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Metachronous oligometastatic prostate cancer-the more the better or only local treatment?].
    Steuber T; Maurer T; Miller K
    Urologe A; 2021 Dec; 60(12):1534-1545. PubMed ID: 34734294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
    Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oligometastatic prostate cancer treatment.
    Rossetti S; Di Napoli M; Pisano C; C Cecere S; Tambaro R; Ventriglia J; Passarelli A; Iovane G; Feroce F; Lastoria S; Di Gennaro F; Muto P; Borzillo V; Di Franco R; Perdonà S; Quarto G; Pignata S
    Future Oncol; 2021 Oct; 17(29):3893-3899. PubMed ID: 34296622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?
    Slaoui A; Albisinni S; Aoun F; Assenmacher G; Al Hajj Obeid W; Diamand R; Regragui S; Touzani A; Bakar A; Mesfioui A; Karmouni T; Ameur A; Elkhader K; Koutani A; Ibnattya A; Roumeguere T; Peltier A
    World J Urol; 2019 Nov; 37(11):2343-2353. PubMed ID: 30706122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.